- Home
- PEBK vs PRQR Comparison
PEBK vs PRQR Comparison
Compare PEBK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | PRQR |
|---|---|---|
| Founded | 1912 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.4M | 244.1M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PEBK | PRQR |
|---|---|---|
| Price | $42.67 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 26.6K | ★ 1.6M |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 21.48 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | $53.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.81 | $1.33 |
| 52 Week High | $45.78 | $3.10 |
Technical Indicators
Market Signals| Indicator | PEBK | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 60.78 |
| Support Level | $41.29 | $1.40 |
| Resistance Level | $43.31 | $1.99 |
| Average True Range (ATR) | 1.18 | 0.14 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 51.19 | 82.47 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.